NeuroSense Therapeutics Ltd. NRSN
Regular-session close
After hours · Nov 13, 4:00 PM ET
- YTD
- -89.01%
- 1 year
- -90.80%
Fundamental scorecard
5 of 25 checks passed on NRSN’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Value 0 of 5
- Failed:P/E below its own 5-year median No profit over FY 2025, so no P/E.
- Failed:P/E under 20 No profit over FY 2025, so no P/E.
- Failed:Price to sales below its own 5-year median Not enough data to decide.
- Failed:Price to book below its own 5-year median Shareholders’ equity is negative.
- Failed:Free cash flow yield above 4% Free cash flow of -7.68M is -239.5% of the market value.
Growth 1 of 5
- No data:Revenue grew over the last year Not enough data to decide.
- No data:Revenue grew more than 5% a year over five years Not enough data to decide.
- Passed:Earnings per share grew over the last year EPS -8.80 against -10.80 in the year before.
- Failed:Earnings per share grew more than 5% a year over five years EPS -10.20 in FY 2020, -8.80 in FY 2025.
- No data:Analysts expect higher earnings per share over the next year No analyst estimate.
Profitability 0 of 5
- Failed:Profitable over the last year Net income of -11.1M over FY 2025.
- Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
- Failed:Return on equity above 15% Return on equity of -4635.4%.
- No data:Net margin above its 5-year average Not enough data to decide.
- Failed:Free cash flow is at least 80% of net income No profit over FY 2025 to compare with.
Financial health 4 of 5
- Failed:Short-term assets cover short-term liabilities Short-term assets of 844K against short-term liabilities of 3.00M.
- Passed:Short-term assets cover long-term liabilities Short-term assets of 844K against long-term liabilities of 0.
- Passed:Net debt under 40% of equity More cash than debt: 231K of cash against 0 of debt.
- Passed:Operating cash flow covers at least 20% of debt The company has no debt.
- Passed:Operating profit covers interest at least 3 times The company has no debt.
Dividend 0 of 5
- Failed:Pays a dividend No dividend paid.
- Failed:Yield above 1.5% No dividend paid.
- Failed:Pays out under 75% of profit No dividend paid.
- Failed:Covered by free cash flow No dividend paid.
- Failed:Not cut in the last five fiscal years No dividend paid.
Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Financial position
What NRSN owns and owes, as of Jun 30, 2026
Short term and long term
Balance sheet · 896K of assets
Liabilities exceed assets, so there is no shareholders’ equity to show.
Debt, equity and cash by year
Now: 231K more cash than debt
- Equity
- Debt
- Cash
Fiscal years, then the newest quarter. Cash includes short-term investments.
From the company’s SEC filings.
Cash flow and returns
How NRSN’s profit turns into cash, and what its capital earns
From profit to free cash flow · FY 2025
Returns on capital · FY 2025
-
-4635.4%
Return on equity
Below the 15% mark · Profit per dollar of shareholders’ equity
-
-406.7%
Return on assets
Below the 5% mark · Profit per dollar of everything it owns
From the company’s SEC filings. The tick on each dial is a common rule-of-thumb level, not a target.
Financial health
Altman Z-Score
-123.19 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
Profitability
Growth (YoY)
Financial Health
Dividends
Annual · latest fiscal year ends 2025-12-31
